Palladone

Neuropathic Pain, Coughing, Pain

Treatment

4 Active Studies for Palladone

What is Palladone

Hydromorphone

The Generic name of this drug

Treatment Summary

Hydromorphone is a powerful opioid pain reliever first used in 1920. It is derived from morphine, but with a few modifications that make it much stronger. Because of its high potency and potential for addiction, hydromorphone is classified as a Schedule II controlled substance. Hydromorphone hydrochloride was first approved by the FDA in 1984 and is available in many forms.

Dilaudid

is the brand name

image of different drug pills on a surface

Palladone Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Dilaudid

Hydromorphone

1926

167

Effectiveness

How Palladone Affects Patients

Hydromorphone has been found to be an effective pain reliever for those who cannot tolerate the side effects of morphine, or those with renal failure or asthma. It is more powerful than morphine, and has a shorter duration of pain relief. When used for acute pain, hydromorphone can cause respiratory depression, slowed thinking, constricted pupils, low blood pressure, dizziness, and vertigo. It also causes less itching and nausea than other pain relievers like meperidine, morphine, diamorphine, bupivacaine, indomethacin, and fentanyl. The respiratory depression is thought to be caused by

How Palladone works in the body

Hydromorphone is a type of opioid medication that is used to reduce pain. It works by binding to mu-opioid receptors, which are located in the brain and spinal cord. Hydromorphone can also depress the respiratory drive and suppress coughs. The effects of the immediate release form of hydromorphone can be felt in about 15-20 minutes and will last for 3-4 hours, while the extended-release form can take effect in 6 hours and remain in the body for 13 hours.

When to interrupt dosage

The proposed dosage of Palladone is contingent upon the determined ailment, comprising Neuropathic Pain, Coughing and Pain. The measure of dosage differs, depending on the method of administration (e.g. Tablet - Oral or Tablet, extended release - Oral) indicated in the table beneath.

Condition

Dosage

Administration

Coughing

8.0 mg, , 12.0 mg, 16.0 mg, 32.0 mg, 3.0 mg, 2.0 mg/mL, 2.0 mg, 10.0 mg/mL, 4.0 mg, 5.0 mg/mL, 0.2 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.4 mg/mL, 1.0 mg, 6.0 mg, 24.0 mg, 30.0 mg, 18.0 mg, 4.5 mg, 9.0 mg, 250.0 mg, 4.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 20.0 mg/mL, 100.0 mg/mL

, Oral, Tablet, extended release, Tablet, extended release - Oral, Suppository - Rectal, Rectal, Suppository, Intramuscular; Intravenous; Subcutaneous, Injection - Intramuscular; Intravenous; Subcutaneous, Injection, Tablet, Tablet - Oral, Parenteral, Injection - Parenteral, Solution - Oral, Solution, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Subcutaneous, Capsule, extended release, Capsule, extended release - Oral, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Oral, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Syrup, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Powder, Powder - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous

Neuropathic Pain

8.0 mg, , 12.0 mg, 16.0 mg, 32.0 mg, 3.0 mg, 2.0 mg/mL, 2.0 mg, 10.0 mg/mL, 4.0 mg, 5.0 mg/mL, 0.2 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.4 mg/mL, 1.0 mg, 6.0 mg, 24.0 mg, 30.0 mg, 18.0 mg, 4.5 mg, 9.0 mg, 250.0 mg, 4.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 20.0 mg/mL, 100.0 mg/mL

, Oral, Tablet, extended release, Tablet, extended release - Oral, Suppository - Rectal, Rectal, Suppository, Intramuscular; Intravenous; Subcutaneous, Injection - Intramuscular; Intravenous; Subcutaneous, Injection, Tablet, Tablet - Oral, Parenteral, Injection - Parenteral, Solution - Oral, Solution, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Subcutaneous, Capsule, extended release, Capsule, extended release - Oral, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Oral, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Syrup, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Powder, Powder - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous

Pain

8.0 mg, , 12.0 mg, 16.0 mg, 32.0 mg, 3.0 mg, 2.0 mg/mL, 2.0 mg, 10.0 mg/mL, 4.0 mg, 5.0 mg/mL, 0.2 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.4 mg/mL, 1.0 mg, 6.0 mg, 24.0 mg, 30.0 mg, 18.0 mg, 4.5 mg, 9.0 mg, 250.0 mg, 4.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 20.0 mg/mL, 100.0 mg/mL

, Oral, Tablet, extended release, Tablet, extended release - Oral, Suppository - Rectal, Rectal, Suppository, Intramuscular; Intravenous; Subcutaneous, Injection - Intramuscular; Intravenous; Subcutaneous, Injection, Tablet, Tablet - Oral, Parenteral, Injection - Parenteral, Solution - Oral, Solution, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Subcutaneous, Capsule, extended release, Capsule, extended release - Oral, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Oral, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Syrup, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Powder, Powder - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous

Warnings

Palladone has twelve contra-indications and should not be administered with any of the conditions in the accompanying table.

Palladone Contraindications

Condition

Risk Level

Notes

Mental Depression

Do Not Combine

narrowing of gastrointestinal tract caused by underlying disease

Do Not Combine

suspected gastrointestinal obstruction

Do Not Combine

opioid intolerance

Do Not Combine

depressed ventilatory function

Do Not Combine

Blind Loop Syndrome

Do Not Combine

Asthma

Do Not Combine

intracranial lesion

Do Not Combine

Esophageal Stenosis

Do Not Combine

Intestinal Pseudo-Obstruction

Do Not Combine

Gastrointestinal obstruction

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Hydromorphone may interact with Pulse Frequency

There are 20 known major drug interactions with Palladone.

Common Palladone Drug Interactions

Drug Name

Risk Level

Description

Azelastine

Major

Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Eluxadoline

Major

The risk or severity of constipation can be increased when Hydromorphone is combined with Eluxadoline.

Ethanol

Major

Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Methylene blue

Major

Hydromorphone may increase the serotonergic activities of Methylene blue.

Mirtazapine

Major

Hydromorphone may increase the serotonergic activities of Mirtazapine.

Palladone Toxicity & Overdose Risk

The toxic dose of hydromorphone in mice is 104mg/kg when taken intravenously and 84mg/kg when taken orally. Overdosing on hydromorphone can cause shallow breathing, sleepiness, weak muscles, cold and clammy skin, constricted pupils, low blood pressure, and even death. Treatment may involve using a ventilator, supportive care, and CPR. Naloxone may be used to reverse respiratory depression. Hydromorphone has not been linked to mutations or cancer, but it has been shown to reduce implantations and live fetuses.

Palladone Novel Uses: Which Conditions Have a Clinical Trial Featuring Palladone?

33 active clinical trials are presently assessing the potential of Palladone to alleviate symptoms of Pain, Neuropathic Pain and Coughing.

Condition

Clinical Trials

Trial Phases

Pain

0 Actively Recruiting

Coughing

0 Actively Recruiting

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Palladone Reviews: What are patients saying about Palladone?

5

Patient Review

4/1/2010

Palladone for Chronic Pain

Pallodone was an amazing drug while it lasted. I have RSD and Palladone really helped me out. Does anyone know if it's still around?
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about palladone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is palladone used for?

"PALLADONE can be used to manage pain in opioid-tolerant patients that is severe enough that it requires treatment with opioids every day and all day long. This is for cases where other treatment options have not been effective."

Answered by AI

Does hydromorphone come in capsules?

"Hydromorphone is used to relieve pain. The extended-release form of hydromorphone is used to relieve pain in opioid-tolerant patients severe enough to require around-the-clock pain relief for a long period of time."

Answered by AI

How do you give a hydromorphone Injection?

"The appropriate dosage for adults is 1-2 mg injected under the skin or into a muscle every 2-3 hours as needed. The doctor may adjust this dosage as necessary. The appropriate dosage for children must be determined by a doctor."

Answered by AI

Is Dilaudid used in UK?

"The psychoactive drug hydromorphone is prohibited in the United Kingdom by the 1971 Misuse of Drugs Act (MDA)."

Answered by AI

Clinical Trials for Palladone

Image of Rush University Medical Center in Chicago, United States.

Hydroxynorketamine for Neuropathic Pain

18 - 75
All Sexes
Chicago, IL

The goal of this randomized double blind three way (1:1:1) cross over clinical trial is to evaluate the effectiveness and duration of analgesia of a single infusion of (2R,6R)-HNK 0.5mg/kg compared with ketamine 0.5mg/kg and saline with a 5-week interval between treatments on pain, pain qualities, physical function, pain interference, sleep disturbance and quality of life in subjects with neuropathic pain of the extremities. The questions that this study will address are: 1. What is the analgesic efficacy of (2R,6R)-HNK on pain intensity and pain qualities in patients with chronic (\>3 month) neuropathic pain (NP). 2. What will be the effective duration of a single infusion of (2R,6R)-HNK in patients with NP. 3. Will (2R,6R)-HNK reduce pain related effects including interference in daily activities of life, sleep disturbances and change the qualities of pain reported by patients. Participants will receive each of the three study drugs in a random order at 5-week intervals over a 15 week period. The drug will be administered as a 45-minute infusion. Participants will complete quantitative sensory and pain evaluations and complete patient reported pain outcomes prior to receiving the first study drug and at 7, 14 and 21 and 35 days following study drug administration.

Phase 1 & 2
Recruiting

Rush University Medical Center

Asokumar Buvanendran, MD